A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

NCT04516447 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

DRUG: Azenosertib
DRUG: Carboplatin
DRUG: Pegylated liposomal doxorubicin
DRUG: Paclitaxel
DRUG: Gemcitabine
BIOLOGICAL: Bevacizumab

Sponsor

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc